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(12.2% vs. 6.2%, p¼0.003) and at one year (26.1% vs. 20.1%, p¼0.046).
Mortality was lower in patients that were additionally treated with
MitraClip system for concomitant moderate to severe MR.
CONCLUSIONS Pre-existing moderate or severe mitral regurgitation
is associated with an 97 % higher mortality at 30 days and 30 % higher
mortality at one year as compared to patients with no or mild MR.
Larger outcome studies are necessary to investigate whether addi-
tional treatment of MR in patients with concomitant moderate to se-
vere MR will improve the prognosis in a TAVR population.
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BACKGROUND Risk of stroke after TAVR is a persistent concern;
identiﬁcation of stroke predictors would be of use in patient selection.
METHODS We examined the frequency and predictors of stroke
among patients in the 2 CoreValve US Pivotal IDE trials and 2
Continued Access studies. Patients were followed prospectively. All
patients underwent physical exam and evaluation with the NIHSS at
baseline, 24 h, hospital discharge, 30 d, and 1 y postprocedure.
Neurologic events lasting >24 h or with concordant imaging abnor-
malities were classiﬁed as strokes. Modiﬁed Rankin Scale >2 deﬁned
major stroke. All rates are K-M estimates. Instantaneous stroke hazard
was modeled with the Epanetchnikov kernel-smoothing function at a
bandwidth ¼ 10 points. Three predictive models were constructed
using Cox Proportional Hazard functions (clinical parameters alone;
clinical and imaging characteristics; clinical, imaging, and procedural
characteristics).
RESULTS 3687 patients (3581 person-y) were included. Stroke
occurred <30 d in 174 (4.8%) and <1 y in 270 (8.4%); major stroke
occurred in 2.8% and 5.0%, respectively. All-cause mortality at 1 y was
45.1% for stroke patients and 63.2% for major stroke patients.
Instantaneous hazard analysis showed an early inﬂection point at 10
d (Fig); 147 (4.1%) strokes occurred in this period. Clinical predictors
of early stroke were total NIHSS >0 (HR¼1.50), PVD (HR¼1.44), prior
TIA (HR¼2.48), no prior CABG (HR¼1.72), angina (HR¼1.64), BMI<21
kg/m2 (HR¼2.14), and falls <6 mo (HR¼1.73). Addition of imaging
parameters did not change clinical predictors, but further addition of
procedural parameters added predictors: rapid pacing during valvu-
loplasty (HR¼9.9), total procedure time (HR¼1.003), and total time
delivery catheter in body (HR¼1.011). Postimplant balloon dilation did
not increase early stroke risk; non-iliofemoral access was of marginal
signiﬁcance (HR¼0.668, P¼0.058).CONCLUSIONS In this ﬁrst prospective examination of stroke after
TAVR within a series of large trials, we observed a biphasic frequency
of stroke with an early hazard occurring <10 d. Clinical predictors
were largely indicators of prior atherosclerotic vascular disease and
frailty indices. Readily available imaging parameters contributed lit-
tle, and procedural parameters reﬂected the complexity of the pro-
cedure. Further reﬁnement of imaging techniques may be of help in
future prediction of early stroke.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) has
been worldwide adopted but there are still multiple areas where
consensus and evidence are lacking. Different approaches, techniques
and imaging tools are actually implemented during the procedure
with several differences according to local clinical practice. The ob-
jectives were to determine the real life practice related to procedural
techniques used during TAVI across different centers around the
world.
METHODS From January to May 2015, an online survey was distrib-
uted worldwide in centers performing TAVI regardless the number of
procedures and valve type. There was a responsible to distribute the
survey for each country or region.
RESULTS A total of 167 centers (including 37843 TAVI procedures)
responded the questionnaire from 27 different countries in Europe,
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in 83% of the cases followed by transapical approach (10%). Most
procedures were performed in a catheterization laboratory (74%) or
hybrid room (29%). An anesthesiologist assisted the transfemoral/
subclavian approach procedures in 94% of centers. General anesthesia
was used systematically in 43% of the centers, and 34% used general
anesthesia occasionally (<25% of patients). TEE guidance was sys-
tematically used in 45% of centers. Valve type was spited half-half
between balloon-expandable (Edwards valve) and self-expandable
(mainly CoreValve) systems. Aortography was the most common
exam used for assessing residual aortic regurgitation (90%), followed
by hemodynamic evaluation (65%) and TEE (55%). Conversely, the
operators relied ﬁrsts on TEE (40%) in case of discrepancies, followed
by aortography (28%) and hemodynamic assessment (21%). Heparin
(99.4%) was the most common anticoagulation therapy during the
procedure, but activated clotting time (ACT) guidance was imple-
mented in only 36% of the centers.
CONCLUSIONS This survey highlights several differences in proce-
dural management particularly among the choice of the primary
anesthetic regimen and the systematic TEE support during TAVI.
Notably, discordance is present regarding the best technique to
evaluate AR after TAVI, one of the most important predictors of long-
term mortality.
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BACKGROUND Redo surgery for degeneration of biological aortic
valve prostheses can be a high-risk procedure. Transcatheter aortic
valve-in-valve implantation poses a less-invasive treatment alterna-
tive for these patients. We aim to present our clinical outcomes of
consecutive patients after a valve-in-valve TAVI (TAV-in-SAV) as
compared to a standard reoperation (SAV-in-SAV) for a failing surgical
bioprosthesis in a single center setting.
METHODS All SAV-in-SAV and TAV-in-SAV patients from January
2001 to October 2014 were retrospectively reviewed. Patients with
previous mechanical or transcatheter valves, active endocarditis and
concomitant cardiac procedures were excluded. Patient characteris-
tics, preoperative data, post-procedural complications and 30-day
mortality were collected from a designated database.
RESULTS Of all reviewed patients, 102 fulﬁlled the inclusion criteria: 50
(49%) underwent a transcatheter valve-in-valve procedure, while 52
(51%) patients underwent redo-surgery. TAV-in-SAV patients were
signiﬁcantly older and had a higher mean logistic EuroSCORE than pa-
tients in the SAV-in-SAV group (78.16.7years vs. 66.213.1years,
P<0.001 and 27.4%18.7% vs. 14.4%10%, P<0.001, respectively). There
was no signiﬁcant difference between the TAV-in-SAV and SAV-in-SAV
group in 30-day mortality (4% vs. 0%; P¼ 0.238), postoperative
myocardial infarction (2% vs. 2%; p¼0.49), stroke (4% vs. 2%; p¼0.614) or
dialysis (12% vs. 2%; p¼0.057). Postoperative pacemaker implantation
and chest tube output were higher in the SAV-in-SAV group compared to
the TAV-in-SAV group (21% vs. 6%, P¼0.042 and 0.91.0l vs. 0.60.9l,
P¼0.047, respectively). Postoperative gradients were signiﬁcantly higher
in the TAV-in-SAV group (18.68.7mmHG vs. 13.85.4mmHg; p¼0.008).
CONCLUSIONS Our study shows, irrespective of different baseline
comorbidities, a low 30-day mortality as well as low postoperative
myocardial infarction and stroke rates in patients with failed aortic bio-
prostheses treated either by surgical redo or transcatheter intervention.
The rate of dialysis in the TAV-in-SAV group as well as the high post-
operative pacemaker rate in the SAV-in-SAV group will require further
evaluation. Nonetheless, older patients or patientswith a high surgical risk
may beneﬁt from the transcatheter valve-in-valve procedure.
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BACKGROUND Subclinical cerebral ischemic lesions are detected by
diffusion- weighted magnetic resonance imaging (DW-MRI) in the
majority of patients after TAVR which may be associated with
impaired short term neurological outcome. The impact of the TAVR
device on cerebral ischemic lesions is not well deﬁned. We aimed to
analyze the incidence of cerebral ischemic lesions in a large cohort of
patients undergoing TAVR with different devices.
METHODS Consecutive high surgical risk patients with severe aortic
valve stenosis treated with TAVR underwent DW-MRI 2-4 days after
the procedure. DW-MRI scans were analyzed for the occurrence,
number and volume of new ischemic lesions by a blinded physician.
RESULTS One-hundred- ﬁfty-two patients were enrolled, the major-
ity received an Edwards SAPIEN 3 (ES 3) (57%), 15.2% an Edwards
SAPIEN XT (ES XT), 23.2% a Direct Flow Medical (DFM), 3.3% a Lotus
and 1.3% an Evolut R aortic valve. Cerebral ischemic lesions were
detected in 70.4%. None of the patients was neurologically symp-
tomatic. Cerebral lesions after TAVR were found for ES XT in 56.5%,
ES 3 in 70.9%, DFM in 85.7%, Lotus in 20% and Evolute R 100% of
patients, respectively, which was statistically signiﬁcant in univariate
analysis. Logistic regression analysis revealed valve type as the only
independent predictor for new cerebral ischemic lesions (p¼0.017).
CONCLUSIONS Asymptomatic cerebral ischemic lesions after TAVR
are observed frequently. The TAVR device type has a signiﬁcant
impact on the incidence of new cerebral ischemic lesions.
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BACKGROUND Registries for transcatheter valve-in-valve procedures
show peri procedural stroke rates of about 2%. Cerebral protection devices
may reduce the stroke rate and histopathology ﬁndings are unknown.
METHODS Twenty-one patients were treated with implantation of
TAVR prostheses into degenerated bioprotheses in the aortic (n¼16)
and mitral position (n¼5), combined with a Claret Cerebral Protection
System (Claret Medical, Inc., Santa Rosa, CA, USA) for cerebral pro-
tection. For TAVI in aortic position 13 Corevalve/Evolut R, 2 Portico
and 1 Sapien valve were used. For bioprostheses in the mitral position
Sapien/Sapien 3 prostheses were exclusively implanted. Access routes
were transfemoral (n¼14), transapical (n¼3), transaxillary (n¼2) and
transseptal (n¼2). Mean patient age was 75  1s years; mean logistic
EuroSCORE was 35.7%. Clinical follow-up by a cardiologist was ob-
tained 3 days after the intervention and at discharge (mean 9 days). In
cases of suspected stroke, a neurologist were consulted. Histological
analyses were performed in 7 patients by the CVPath Institute in
Gaithersburg, MD (additional 3 analyses are in progress).
RESULTS TAVR device success rate was 77% due to high mean gradi-
ents for implantations in the aortic position. Stroke rate up to discharge
was 0%. TAVI device success rate was 77% due to high mean gradients
